經緯輝開(300120.SZ):新雷基金及一致行動人合計持股比例降至5%以下
格隆匯2月6日丨經緯輝開(300120.SZ)公佈,公司於近日收到公司股東浙江海寧新雷盈創投資合夥企業(有限合夥)及其一致行動人出具的《天津經緯輝開光電股份有限公司簡式權益變動報告書》,其於2020年2月4日通過大宗交易方式減持公司無限售條件流通股146萬股,佔公司總股本比例0.3141%。
此次權益變動完成後,浙江海寧新雷盈創投資合夥企業(有限合夥)及其一致行動人浙江海寧瑞業投資合夥企業(有限合夥)合計持有公司股份數為2323.6581萬股,佔公司總股本的4.9997%,持有公司股份比例降至5%以下。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.